Apimeds Pharmaceuticals US, Inc. APUS
Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) is a pain/anesthesia drug developer. Its lead program, APITOX, is in Phase 2 for Pain associated with osteoarthritis (and other indications). Its next catalyst on record is APITOX (Lokahi BioBusiness): Contemplated spin-off of the BioBusiness / distribution of 51% of Lokahi equity (approx. twelve months from 2026-04-24) (2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: APITOX (Lokahi BioBusiness) — Contemplated spin-off of the BioBusiness / distribution of 51% of Lokahi equity (approx. twelve months from 2026-04-24) (2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| APITOX | Pain associated with osteoarthritis | unclear | Phase 2 |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 pain/anesthesia companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.